After-Hours Movers 11/29: (CPIX) (ADAG) (OM) Higher; (LIZI) (INTU) Lower (more...)

StreetInsider2021-11-30

After-Hours Movers Cumberland Pharmaceuticals129% HIGHER; announced the U.S. Food and Drug Administration (FDA) has approved expanded labeling for Caldolor®, an intravenously delivered formulation of ...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

小虎一飞冲天
2021-11-30
小虎一飞冲天
Like pls. Thanks.
- ArcherWG:
  👌🏻
JeremyChuax
2021-11-30
JeremyChuax
Like pls.
- ACECHUA:
  Wow
- Elsontok:
  done
HENRYCSC
2021-11-30
HENRYCSC
Thanks
- JeremyChuax:
  Up
Dreamchaser9
2021-11-30
Dreamchaser9
Ok
- 小虎一飞冲天:
  👍🏼
DMC8
2021-11-30
DMC8
Like pls
- AlphaKK:
  ok
玉树临风英俊
2021-11-30
玉树临风英俊
👌

发表看法

182

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/2187309181?lang=zh_CN&edition=full","thumbnail":"","is_english":true,"pubTime":"2021-11-30 07:03","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2187309181","market":"us","top_or_hot":-1,"title":"After-Hours Movers 11/29: (CPIX) (ADAG) (OM) Higher; (LIZI) (INTU) Lower (more...)","media":"StreetInsider","content":"<div>\n<p>After-Hours Movers\nCumberland Pharmaceuticals129% HIGHER; announced the U.S. Food and Drug Administration (FDA) has approved expanded labeling for Caldolor®, an intravenously delivered formulation of ...</p>\n\n<a href=\"https://www.streetinsider.com/dr/news.php?id=19284469\">网页链接</a>\n\n</div>\n","source":"highlight_streetinsider","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>After-Hours Movers 11/29: (CPIX) (ADAG) (OM) Higher; (LIZI) (INTU) Lower (more...)</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAfter-Hours Movers 11/29: (CPIX) (ADAG) (OM) Higher; (LIZI) (INTU) Lower (more...)\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-11-30 07:03 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.streetinsider.com/dr/news.php?id=19284469><strong>StreetInsider</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>After-Hours Movers\nCumberland Pharmaceuticals129% HIGHER; announced the U.S. Food and Drug Administration (FDA) has approved expanded labeling for Caldolor®, an intravenously delivered formulation of ...</p>\n\n<a href=\"https://www.streetinsider.com/dr/news.php?id=19284469\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4528","symbol_name":"SaaS概念","start_time":0,"source_url":"https://www.streetinsider.com/dr/news.php?id=19284469","article_id":"2187309181","we_media_id":null,"thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2187309181","pubTimestamp":1638226980,"sourceInfo":{"source_id":"highlight_streetinsider","name":"StreetInsider"},"weMediaInfo":null,"summary":"After-Hours Movers\nCumberland Pharmaceuticals129% HIGHER; announced the U.S. Food and Drug Administr","collect":0,"end_time":0,"defaultTopTitle":"streetinsider.com","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4528":"SaaS概念","BK4533":"AQR资本管理(全球第二大对冲基金)","OM":"Outset Medical Inc.","BK4007":"制药","BK4023":"应用软件","INTU":"财捷","ADAG":"天演药业","CPIX":"坎伯兰药业","BK4551":"寇图资本持仓","BK4557":"大麻股","BK4082":"医疗保健设备","BK4567":"ESG概念","BK4534":"瑞士信贷持仓","BK4139":"生物科技","BK4108":"电影和娱乐"},"translate_title":"下班后11/29：(CPIX)(ADAG)(OM)更高；(LIZI)（INTU）Lower（More...）","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"ADAG":0.9,"CPIX":0.9,"INTU":0.9,"LIZI":0.9,"OM":0.9},"content_text":"After-Hours Movers\nCumberland Pharmaceuticals129% HIGHER; announced the U.S. Food and Drug Administration (FDA) has approved expanded labeling for Caldolor®, an intravenously delivered formulation of ibuprofen, to now include use in pre-operative administration. The non-narcotic pain reliever may now be administered just prior to surgery to enable patients to wake up from their procedure in significantly less pain.\nAdagene 12.1% HIGHER; announced that the U.S. Food and Drug Administration (FDA) has cleared the Investigational New Drug (IND) application to proceed with a Phase 1b/2 clinical trial of its anti-CTLA-4 monoclonal antibody (mAb), ADG116, in combination with the anti-PD-1 antibody, pembrolizumab. The global trial (ADG116-P001 / KEYNOTE-C97) will evaluate patients with advanced/metastatic solid tumors at multiple sites in the U.S. and Asia Pacific (APAC).\nOutset Medical Inc. 5.6% HIGHER; announced today that the U.S. Food and Drug Administration (FDA) has granted 510(k) clearance for a new sterilization method of the cartridge utilized in its TabloÂ® Hemodialysis System, enabling full production in North America. The Tablo cartridge is a single-use disposable that works in concert with the console to deliver dialysis treatment. Its 'one-touch' design speeds and simplifies treatment set-up and take-down.\nLIZHI Inc 4.8% LOWER; Reports Q3 Revenues of $78.4M, Average Total MAUs of 58.9M, Adjusted Net Loss of $4.2M\nKrystal Biotech Inc. 4.3% HIGHER; adds to 121% intra-day gains after it announced that it has commenced a $200 million underwritten public offering of its common stock.\nErytech Pharma S.A. 4% HIGHER; announced the granting of US patent 11,141,468, covering methods of treating solid tumors by administering methioninase and asparaginase. In total, ERYTECHs IP portfolio now includes 16 global patent families with over 310 patents and 45 applications. These patent families protect ERYTECHs proprietary red blood cell encapsulation technology (ERYCAPS®), its therapeutics for Oncology, Rare Metabolic Diseases, and Immune Modulation, as well as its methods for producing Cargo-Loaded Red Cell Extracellular Vesicles (CLRCEV).\nIntuit 2.5% LOWER; announced today that certain entities affiliated with Dan Kurzius, co-founder of Mailchimp have commenced an underwritten secondary offering of 1,548,700 shares of the Company's common stock.\nR.R.Donnelley 2.2% HIGHER; Chatham Asset Management, LLC, a private investment firm which manages funds that beneficially own approximately 14.9% of the outstanding common stock of R.R. Donnelley & Sons Company (NYSE: RRD) and which is the largest bondholder of the Company, today responded to a press release issued by RRD regarding the expiration of its go-shop period and receipt of an offer from a strategic party to acquire RRD at a price equal to $10.00 per share in cash.\nGolub Capital BDC 2.1% HIGHER; reported Q4 EPS of $0.42, $0.12 better than the analyst estimate of $0.30.","kind":null,"is_publish_news":true,"is_publish_highlight":false,"is_publish_live":null,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[{"id":609340768,"gmtCreate":1638243377480,"gmtModify":1638243383483,"author":{"id":"3582098623642517","authorId":"3582098623642517","name":"小虎一飞冲天","avatar":"https://static.tigerbbs.com/1a55a61195830e019abf5d3cc69681b9","vip":1,"crmLevel":5,"crmLevelSwitch":0},"htmlText":"Like pls. Thanks.","listText":"Like pls. Thanks.","text":"Like pls. Thanks.","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/609340768","repostId":2187309181,"repostType":4,"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":6789958,"gmtCreate":1638313970055,"gmtModify":1638313970085,"authorId":3581837121803380,"author":{"id":3581837121803380,"authorId":3581837121803380,"name":"ArcherWG","avatar":"https://static.laohu8.com/default-avatar.jpg","vip":1,"crmLevel":2,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":609340768,"type":1,"supId":0,"prevId":0,"content":"👌🏻","text":"👌🏻","html":"👌🏻"}],"langContent":"CN"},{"id":609316269,"gmtCreate":1638238444604,"gmtModify":1638238444737,"author":{"id":"4089499026613770","authorId":"4089499026613770","name":"JeremyChuax","avatar":"https://static.tigerbbs.com/a1f1ede120de2da723e4456d7fdcce55","vip":1,"crmLevel":2,"crmLevelSwitch":0},"htmlText":"Like pls.","listText":"Like pls.","text":"Like pls.","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":2,"repostSize":0,"link":"https://laohu8.com/post/609316269","repostId":2187309181,"repostType":2,"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":6780631,"gmtCreate":1638245989130,"gmtModify":1638245989218,"authorId":3583096540214259,"author":{"id":3583096540214259,"authorId":3583096540214259,"name":"ACECHUA","avatar":"https://static.tigerbbs.com/3d6bf1e1542321e4f354a78287c1e560","vip":1,"crmLevel":5,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":609316269,"type":1,"supId":0,"prevId":0,"content":"Wow","text":"Wow","html":"Wow"},{"id":6779169,"gmtCreate":1638238578683,"gmtModify":1638238578714,"authorId":3577246510298951,"author":{"id":3577246510298951,"authorId":3577246510298951,"name":"Elsontok","avatar":"https://static.tigerbbs.com/5d91c4e73ceffea4b93c2c832535db3b","vip":1,"crmLevel":2,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":609316269,"type":1,"supId":0,"prevId":0,"content":"done","text":"done","html":"done"}],"langContent":"CN"},{"id":609330300,"gmtCreate":1638237261762,"gmtModify":1638237467027,"author":{"id":"3575091428590185","authorId":"3575091428590185","name":"HENRYCSC","avatar":"https://static.tigerbbs.com/6d47a6dec25b21dc547a5b982674c499","vip":1,"crmLevel":2,"crmLevelSwitch":0},"htmlText":"Thanks&nbsp;","listText":"Thanks&nbsp;","text":"Thanks","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/609330300","repostId":2187309181,"repostType":4,"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":6779146,"gmtCreate":1638238439368,"gmtModify":1638238439401,"authorId":4089499026613770,"author":{"id":4089499026613770,"authorId":4089499026613770,"name":"JeremyChuax","avatar":"https://static.tigerbbs.com/a1f1ede120de2da723e4456d7fdcce55","vip":1,"crmLevel":2,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":609330300,"type":1,"supId":0,"prevId":0,"content":"Up","text":"Up","html":"Up"}],"langContent":"CN"},{"id":609922158,"gmtCreate":1638233158118,"gmtModify":1638233219908,"author":{"id":"3581782846197879","authorId":"3581782846197879","name":"Dreamchaser9","avatar":"https://static.tigerbbs.com/f4f8f000953179179078bdd5e6f748b6","vip":1,"crmLevel":3,"crmLevelSwitch":0},"htmlText":"Ok","listText":"Ok","text":"Ok","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/609922158","repostId":2187309181,"repostType":4,"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":6780159,"gmtCreate":1638243387302,"gmtModify":1638243387403,"authorId":3582098623642517,"author":{"id":3582098623642517,"authorId":3582098623642517,"name":"小虎一飞冲天","avatar":"https://static.tigerbbs.com/1a55a61195830e019abf5d3cc69681b9","vip":1,"crmLevel":5,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":609922158,"type":1,"supId":0,"prevId":0,"content":"👍🏼","text":"👍🏼","html":"👍🏼"}],"langContent":"CN"},{"id":609989557,"gmtCreate":1638231339851,"gmtModify":1638231341370,"author":{"id":"3579992296424941","authorId":"3579992296424941","name":"DMC8","avatar":"https://static.tigerbbs.com/65aa8f5f6299558ce2ab36482793f750","vip":1,"crmLevel":2,"crmLevelSwitch":0},"htmlText":"Like pls&nbsp;","listText":"Like pls&nbsp;","text":"Like pls","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":7,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/609989557","repostId":2187309181,"repostType":4,"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":6778324,"gmtCreate":1638235875839,"gmtModify":1638235875929,"authorId":3572817570586604,"author":{"id":3572817570586604,"authorId":3572817570586604,"name":"AlphaKK","avatar":"https://static.tigerbbs.com/31614816d2f82318ead2a8b020b02b0f","vip":1,"crmLevel":2,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":609989557,"type":1,"supId":0,"prevId":0,"content":"<u>ok</u>","text":"<u>ok</u>","html":"<u>ok</u>"}],"langContent":"CN"},{"id":609917468,"gmtCreate":1638231224664,"gmtModify":1638231225526,"author":{"id":"3580076354872466","authorId":"3580076354872466","name":"玉树临风英俊","avatar":"https://static.laohu8.com/default-avatar.jpg","vip":1,"crmLevel":2,"crmLevelSwitch":0},"htmlText":"👌&nbsp;","listText":"👌&nbsp;","text":"👌","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":6,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/609917468","repostId":2187309181,"repostType":4,"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"CN"}],"isCommentEnd":false,"newsSizeData":{"likeSize":182,"commentSize":8,"repostSize":0,"favoriteSize":1,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.25.1","shortVersion":"4.25.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2187309181"}